Breakthrough in Lupus Treatment: Fate Therapeutics Initiates First-of-its-Kind CAR-T Cell Study
In a significant advancement in the treatment of autoimmune diseases, Fate Therapeutics has announced the commencement of a pioneering clinical study targeting systemic lupus erythematosus (SLE), commonly known as lupus. This marks the first time a patient with lupus has been treated using an “off-the-shelf” chimeric antigen receptor (CAR) T-cell therapy, a groundbreaking approach that […]
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology […]
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology’s 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT […]